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Abstract
BACKGROUND: The outbreak of the new coronavirus was first reported in China and then spread to other parts of 
the world. The number of people infected with the virus is significantly increasing, making the disease an international 
concern. 
AIM: The present study aimed to investigate the coronavirus and its effects on children. 
MATERIALS AND METHODS: In the present study, search engines, and scientific databases of Google Scholar, 
Science Direct, PubMed, Medline, and Cochrane were searched to examine the effect of coronavirus on children. To 
collect information, keywords were also searched in the databases. 
RESULTS: In spite of contradictory results, among the children, those under 5 years old are the high-risk group. 
CONCLUSION: Some researchers believe that the virus shows fewer symptoms in children. However, the immune 
system of infants under six months develops pneumonia in rare cases.
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Introduction
Coronavirus (CoV) is a severe infectious agent 
in human and animal, which causes systemic disorder 
in respiratory and gastrointestinal tracts. CoV can 
infect certain species of animals, including mammals, 
bird, and reptiles [1]. On January 3, 2020, a new 
member of the CoV enveloped RNA was identified in 
bronchoalveolar lavage fluid samples of a patient in 
Wuhan and subsequently confirmed as the cause of 
the disease by the Centers for Disease Control and 
Prevention (CDC, China) [2]. The pathogenicity of this 
virus is that after the virus enters the body, it first binds 
to specific receptors on the cells with proper binding 
feature. Then, it enters the cell and uses its transcription 
machinery, multiplying it in large numbers and causing 
cellular damage [3].
Most of the patients are adults, with a small 
number of children. Out of 44,672 laboratory-confirmed 
cases of COVID-19 in China, only 2.1% are under 19 
years old.
Studies have shown that COVID-19 has the 
highest mortality in the elderly. It also causes mild-to-
severe respiratory problems in children, with mortality 
and morbidity lower than other age groups. Most 
children patients show mild symptoms, with no fever or 
signs of pneumonia [4], [5], [6], [7].
Given that one of the concerns of the health 
sector regarding the dangerous consequences of CoV 
is the dangers of this disease in a vulnerable community 
of children. There are many questions about the effect 
of the virus and ways to prevent children from getting 
the disease. An important issue is recognizing the virus 
and providing a reliable treatment strategy such as 
vaccination. Therefore, in the present study, an attempt 
is made to examine its effect on children and the 
proposed treatment options by examining the published 
articles on COVID-19 and the development of new CoV 
in children.
Materials and Methods
Search strategy
This evaluation was conducted in January 
and February 2020. Search engines and scientific 
databases of Google Scholar, Science Direct, PubMed, 
Medline, and Cochrane were used for obtaining papers 
on CoV and its effect on children. The keywords were 
also searched in the databases to collect information 
on the CoV, including corona, CoV and children, CoV 
pathogenesis, the virus structure, and COVID-19. 
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Priority was given to articles from the past year. A 
reference list of relevant articles was searched to identify 
additional articles. In addition, search engines such as 
Google and Google Scholar were used to identify all 
potential eligible publications. The operators were used 
to find related articles. The study was conducted from 
July 5, 2020, to September 5, 2020.
Inclusion and exclusion criteria
Inclusion criteria included articles published 
after December 1997 to the end of January 2020, 
qualitative, descriptive, analytical study and articles 
published in English and Persian. Editorial letters, 
case studies, and clinical studies were excluded. 
Furthermore, articles with inadequate reports and a 
study whose full text was not available were excluded 
from the study.
Screening and data mining
A trained author performed search strategies. 
In the first stage, the titles and abstracts were 
reviewed for the selection of articles, in the next 
stage, an author independently reviewed the full text 
of the articles. Differences in findings were resolved 
through the criterion method of general conclusion of 
articles and in this study, were organized. Qualitative 
evaluation of articles was done by preparing a list 
of titles and summaries of studies in databases and 
selecting them based on the purpose of the study and 
content.
CoVs
CoVs are a large family of viruses that cause 
a flu-like illness in birds and mammals, accounting 
for 15–30% of common colds. They are spherical 
or polymorphic viruses containing a positive-sense 
single-stranded RNA with protein capsid nucleoprotein. 
There are several CoVs common between human and 
animal that usually cause mild-to-moderate infections 
in upper respiratory tract, such as the common cold. 
The virus rarely evolves and transmits from other 
animals to human. COVID-19 is a mutant of the CoVs 
family [2], [8].
The recombination rate of the virus is high 
because of the RNA-dependent RNA polymerase 
transcription (RdRPs) and constant transcription 
errors. However, despite the high mutation, CoVs 
are a zoonotic pathogens that vary between human 
and animal with a wide range of clinical manifestation 
from asymptomatic to requiring hospitalization due to 
infection in the respiratory, gastrointestinal, liver, and 
nervous systems [9], [10]. CoV is structurally related 
to middle East respiratory syndrome and severe acute 
respiratory syndrome (SARS).
CoV, SARS, and MERS
6LU7 is the COVID-19 main protease (Mpro), 
which been structured and repositioned in PDB and 
can be accessed by the public, as of early February 
2020. The Mpro of 2019-nCov shares 96% similarity 
with the Mpro of the SARS-CoV [11]. The Mpro in CoV 
is essential for the proteolytic maturation of the virus 
and has been examined as a potential target protein 
to prevent the spread of infection by inhibiting the 
cleavage of the viral polyprotein [12]. The discovery 
of the structure of the Mpro proteinase in COVID-19 
provides an excellent opportunity to identify potential 
drug candidates for treatment.
Proteins represent potential targets for the 
inhibition of CoV replication, and the protein sequences 
of the SARS-CoV Mpro and 2019-nCoV Mpro are 
96% identical, and the active sites in both proteins 
remain free from mutation. Thr24, Thr26, and Asn119 
amino acids are predicted to be involved in drug 
interactions [13]. Therefore, usually, host proteases 
can be used as potential therapeutic targets. In 
many viruses, proteases play important roles in viral 
replication; therefore, proteases are commonly used as 
protein targets during the development of antiviral drug 
treatment [14].
Nelfinavir and lopinavir are protease inhibitors 
with high cytotoxic against HIV-infected cells. Lopinavir 
and ritonavir are protease inhibitors recommended for 
the treatment of SARS and MERS, which have similar 
mechanisms of action as HIV. The antiviral effects of 
nelfinavir on CoV have been studied in vitro, in Vero 
cells infected with SARS-CoV [15], [16]. It is important 
to pay attention to how infection develops in COVID-19 
disease.
Infection
Scientists exploring how CoVs like COVID-19 
infect human cells have shown that the SARS-CoV-2 
spike (S) glycoprotein binds to the cell membrane 
protein angiotensin-converting enzyme 2 (ACE2) to 
enter human cells. COVID-19 has been shown to bind 
to ACE2 through the S protein on its surface. During 
infection, the S protein is cleaved into subunits, S1 
and S2. S1 contains the receptor binding domain 
(RBD) which allows CoVs to directly bind to the 
peptidase domain (PD) of ACE2. S2 then likely plays 
a role in membrane fusion. Chinese researchers have 
now used cryogenic electron microscopy to study the 
structure of the ACE2 when it is bound to one of its 
typical ligands, the amino acid transporter B0AT1, and 
also how the COVID-19 RBD may bind to the ACE2-
B0AT1 complex. These structures have previously not 
been identified and could aid in producing antivirals 
or a vaccine that can block CoV infection by targeting 
ACE2 (Figure 1) [3].
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The signs, symptoms, disease 
progression, and severity
Symptoms of COVID-19 are non-specific and 
the disease presentation can range from no symptoms 
(asymptomatic) to severe pneumonia and death. As of 
February 20, 2020, and based on 55,924 laboratory-
confirmed cases, typical signs and symptoms include 
fever (87.9%), dry cough (67.7%), fatigue (38.1%), 
sputum production (33.4%), shortness of breath 
(18.6%), sore throat (13.9%), headache (13.6%), 
myalgia or arthralgia (14.8%), chills (11.4%), nausea 
or vomiting (5.0%), nasal congestion (4.8%), diarrhea 
(3.7%), and hemoptysis (0.9%), and conjunctival 
congestion (0.8%) (WHO, 2019).
People with COVID-19 generally develop signs 
and symptoms, including mild respiratory symptoms 
and fever, on an average of 5–6 days after infection 
(mean incubation period 5–6 days, range 1–14 days) 
(WHO, 2019).
Most people infected with COVID-19 virus 
have mild disease and recover. Approximately 80% 
of laboratory confirmed patients have had mild–
to-moderate disease, including non-pneumonia and 
pneumonia cases, 13.8% have severe disease. 
Asymptomatic infection has been reported, but 
the majority of the relatively rare cases who are 
asymptomatic on the date of identification/report 
went on to develop disease. The proportion of truly 
asymptomatic infections is unclear but appears to be 
relatively rare and does not appear to be a major driver 
of transmission. People at high risk for serious illness 
and death include people over 60 years and those with 
underlying conditions such as hypertension, diabetes, 
cardiovascular disease, chronic respiratory disease, 
and cancer. Disease in children appears to be relatively 
rare and mild, with approximately 2.4% of all reported 
cases among cases under 19 years old. A very small 
proportion of those under 19 had severe (2.5%) or 
critical (0.2%) disease [17], [18], [19].
Mortality increases with age, with the highest 
mortality among people over 80 years of age (case 
fatality rate [CFR] 21.9%). The CFR is higher among 
males compared to females (4.7% vs. 2.8%). By 
occupation, patients who reported being retirees had 
the highest CFR at 8.9%. While patients who reported 
no comorbid conditions had a CFR of 1.4%, patients 
with comorbid conditions had much higher rates: 
13.2% for those with cardiovascular disease, 9.2% 
for diabetes, 8.4% for hypertension, 8.0% for chronic 
respiratory disease, and 7.6% for cancer [19].
CoVs in children
According to a new study, CoV disease 
2019 (COVID-19) has shown mild symptoms among 
children in China. However, the young age group is 
not entirely aware of the virus. Infants had a higher 
disease rate than older children. It is suggested 
that further investigation is needed to understand 
the role of children in the spread of the virus in the 
community. Approximately 75% of suspected children 
had COVID-19. Regarding the gender, no significant 
difference was observed. Approximately 4% of children 
patients were asymptomatic, 51% had mild and 39% 
had moderate symptoms. Moreover, compared to 
18.5% of adults, approximately 6% of children showed 
severe or critical condition (with a 14-year-old boy dead). 
The gap is perceived to be confusing to researchers, 
suggesting that it may be related to both exposure and 
host factors. Several reasons were proposed, including 
(a) children’s low exposure to the virus; (b) high levels of 
antibodies against viruses; and (c) developing different 
immune responses. The virus may also not bind to 
children’s cells. The present study also found that the 
illness in infants is more serious than in older children. 
Compared to 7% of children aged 1–5 years, only 11% 
of infants had severe or critical condition [20]. A similar 
study suggested that children are more susceptible to 
upper respiratory tract involvement rather than lower 
respiratory tract involvement. There is also evidence of 
stool shedding for several weeks after diagnosis leading 
to concerns about oral–fecal transmission of the virus, 
especially in infants and toddlers who are not toilet 
trained, and for viral replication in the gastrointestinal 
tract [6].
Data on individuals aged 18 years old and 
under suggest that there is a relatively low attack rate 
in this age group (2.4% of all reported cases). Within 
Wuhan, among testing of ILI samples, no children were 
positive in November and December of 2019 and in the 
first 2 weeks of January 2020. From available data, and 
in the absence of results from serologic studies, it is 
not possible to determine the extent of infection among 
children, what role children play in transmission, whether 
children are less susceptible or if they present differently 
clinically (i.e., generally milder presentations). The Joint 
Mission learned that infected children have largely 
been identified through contact tracing in households of 
adults. Of note, people interviewed by the Joint Mission 
Team could not recall episodes in which transmission 
occurred from a child to an adult [19].
Figure 1: (a) Connection of the S1 receptor to the ACE2 receptor on 
the pulmonary cells. (b) Three-dimensional structure of the coupled 
receptor. S1 contains the receptor binding domain which allows 
coronaviruses to directly bind to the peptidase domain of ACE2
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Clinical manifestations
The virus was found in pediatric patients, 
from 1-month-old infants to 19 years old, and based 
on the evidences, most have been infected by family 
members [4]. General symptoms of the early patients 
included fever 98%, cough 76%, muscle aches or fatigue 
44%, shortness of breath (in 2 months old infants, with 
cough, difficulty breathing, and breathing faster than 
60/min; in 1–5 years old infants, with cough, difficulty 
breathing, and breathing faster than 40 breaths/min) 
55%, and acute respiratory distress syndrome (ARDS) 
29%. In another study, lymphopenia (a decrease in the 
number of lymphocytes in the blood) was seen in 80% 
of adult patients, while <25% of children patients had 
mild lymphopenia, indicating the severity of infection 
in these patients. Chest computed tomography (CT) of 
children showed only one patient with bilateral ground-
glass opacity, as in adults [5]. In another report by Xia 
on 20 children, 70% of cases showed leukopenia, 10% 
leukocytosis, and 35% lymphopenia. Eight cases were 
found to be infected with other respiratory pathogens 
such as mycoplasma and influenza. Lung scan also 
showed 10 abscesses on both sides of the lung. In 
6 cases, only one side of the lung had abscess, and in 
12 cases, there observed ground-glass opacities [21].
General symptoms include fever 99%, 
dry cough 59%, and muscle pain or fatigue 70%. 
Furthermore, 26% of patients were transferred to ICU 
and 4% of them died. Interestingly, 41% of patients were 
infected in hospitals. Severe cases of ARDS and acute 
kidney failure have also been reported. Symptoms the 
patients may develop include increased C-reactive 
protein (CRP) protein, erythrocyte sedimentation rate, 
lactate dehydrogenase, creatinine, and prothrombin 
clotting time [17]. Another study by Wei et al. indicated 
that all children were infected by their family members, 
showing mild symptoms [22].
Inflammatory markers including CRP and 
procalcitonin showed a 13.6% and 10.6% increase, 
respectively [10]. After studying four infected children, 
two showed respiratory disorder and one severe 
decrease (1 mg/L) in CRP. It is while both proteins in the 
progressed stages significantly increased in adults [23]. 
Children CT showed opacity in different regions. The 
damage was largely similar to that of adults (Figure 2). 
An important issue was the change in CRP protein 
and lymphocytes, in which, while the latter had many 
changes, the former changed a little, indicating a 
significant difference compared to adults [23], [24].
Important points
There are several salient points from this article. 
First, although children are less likely than older adults to 
become severely ill, there are subpopulations of children 
with an increased risk for more significant illness. 
These data on disease severity are consistent with 
data on non-COVID-19 CoVs. The authors of one viral 
surveillance study in a PICU in China reported that CoV 
was detected in more children with ARDS than Human 
metapneumovirus [27]. The authors of another study 
conducted on hospitalized Norwegian children detected 
CoVs in 10% of hospitalized children with respiratory 
tract infections [6]. Younger age, underlying pulmonary 
pathology, and immune compromising conditions have 
been associated with more severe outcomes with non-
COVID-19 CoV infections in children [28].
Second, the attributable risk for severe disease 
from COVID-19 in children is challenging to discern. 
The previous studies have revealed that children from 
whom CoVs are detected from the respiratory tract can 
have viral coinfections in up to 75% of cases [27]. In 
the study by Dong et al. [4], testing for other viruses 
was not standardized, and two-thirds of cases were 
clinically diagnosed, not virologically confirmed. In 
addition, children without virological confirmation were 
more likely to have severe disease than children from 
whom COVID-19 was detected, potentially because 
their symptoms were caused by other pathogens [29].
Third, children may play an important role in 
community-based viral transmission.
Fourth, most children are at a high level of 
immune function. According to studies, while the 
lymphocytes had many changes, the CRP protein 
changed a little [24]. Studies showed that an increase 
in lymphocytes is associated with specific immunity. 
In people with stronger immune system, lymphocytes, 
especially T lymphocytes, act more rapidly and 
specifically eliminate the pathogen. On the other hand, 
in people with weaker immune system, COVID-19 
Figure 2: (a) Computed tomography (CT) of a 10-year-old boy 
showing multiple opacities in lower lobes of both lungs (arrow); 
(b) CT of a 1.5-year-old girl showing multiple ground-glass opacities 
with a big patchy opacity in the right lung (arrows); (c) an axial CT 
image obtained without intravenous contrast in a 42-year-old male in 
the “late” time group (10 days from symptom onset to this CT) shows 
bilateral consolidative opacities, with a striking peripheral distribution 
in the right lower lobe (solid arrows), and with a rounded morphology 
in the left lower lobe (dashed arrow); (d) an axial CT image obtained 
without intravenous contrast in a 56-year-old female shows ground-
glass opacities with a rounded morphology (arrows) in the right 
middle and lower lobes. The left lung was normal [25], [26]
dc
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exacerbates inflammation by causing pneumonia 
and increased cytokines. Similarly, the SARS virus 
is associated with a sharp decrease in the number of 
T-cells in the blood [30], [31], [32], [33]. The bottom 
line is that most children produce less inflammatory 
protein because of their immune system, and 
instead lymphocytes do their job. However, in people 
with weaker immune system, especially adults and 
the elderly, inflammatory proteins are produced, 
increasing the inflammation and worsening of CoV.
Specific safety in children and 
COVID-19
The human immune system is a complex 
network of specialized cells, tissues, and organs that are 
responsible for identifying and eliminating pathogens. 
Intrinsic and specific immune systems are the two main 
parts of the immune system. Intrinsic immunity is a 
general defense system consisting of inhibitory factors 
such as mucosa and skin and a specific immune system 
composed of cells that, with advanced mechanisms, 
identify only certain pathogens. In viral infection, T 
lymphocytes play the most important role in specific 
immunity. In summary, these viruses are specifically 
identified and killed by lymphocytes in a very complex 
cellular response [34], [35], [36]. Normally, after 
detection of viral compounds by cellular receptors, an 
appropriate and effective antiviral response is initiated 
by the immune system, which includes the production 
of a variety of cytokines and immune and inflammatory 
responses. Interferons I (IFN_β and IFN-α molecules) 
are key cytokines produced after virus infection 
that induces the onset of an immune response and 
subsequent adaptation [37], [38]. The immune response 
to the CoV is that CoV infects macrophages and then 
the macrophages deliver CoV antigen to the T cell. This 
process leads to the activation and detection of T cells 
and the increase in the production of various cytokines, 
followed by the widespread release of cytokines to 
enhance the immune response. Continued production 
of these mediators has a negative effect on NK function 
and T cell activation [38].
In people with stronger immune systems, 
lymphocytes, especially T cells, act more rapidly and 
specifically kill the pathogen. However, in people with 
a weaker immune system, COVID-19 causes acute 
inflammation by causing pneumonia and increasing 
cytokines and decreasing T cells [30], [39], [40].
This suggests a large role for lymphocytes 
in specific immunity in relation to their impact on the 
recovery of corona disease. The important results 
of the reviewed articles show that there are a large 
number of T cells in children, which have an impact on 
the quality of function of the specific immune system 
in children. In many children, milder symptoms have 
been observed than in adults due to the specific 
function of the immune system [24]. The reason for 
the strength of the immune system of children compared 
to adults can be summarized in several issues. First, 
children are exposed to a variety of pathogens for the 1st 
time in the early years of life, and second, children have 
the ability to rapidly produce natural antibodies with broad 
reactivity that has not yet been selected and shaped by 
the reaction to common environmental pathogens that are 
more prepared to fight T cells in the body [41], [42], [43].
Treatment
A recent paper reports the inhibitory effect of 
Ramsdevir (a new antiviral drug) and chloroquine (an old 
antimicrobial drug) on the growth of SARS-CoV-2 in vitro 
and an initial clinical trial conducted on Chinese patients 
with COVID-19. It was also shown that chloroquine had 
a significant effect on the clinical outcome and clearance 
of the virus compared to the control groups [44].
Chinese experts recommend that patients 
with mild, moderate, and severe COVID-19 pneumonia 
without chloroquine contraindication be treated with 500 
mg of chloroquine twice daily 10 days. On the other 
hand, 18,264 (24%) reported cases have improved as of 
February 20. An encouraging report on February 20 from 
the Guangdong CDC indicated that out of 125 severe 
cases, 33 (26.4%) were recovered and discharged and 58 
(46.4%) recovered and classified as mild/moderate cases 
(i.e., + mild pneumonia). Of course, there have also been 
severe cases, with 13.4% of deaths so far. Early detection 
and contact with physician may improve treatment [19].
Other adjunctive treatments in China with the 
help of Chinese medicine have been performed on 
COVID-19 patients, including use of antioxidants. The 
current studies in China show that antioxidants are 
effective in boosting the immune system and reducing 
inflammation in patients with COVID-19 [45], [46], [47]. 
Another treatment currently under trial is the production 
of the vaccine; however, because of the consecutive 
mutations in the viral antigens, the investigations mostly 
focused on inhibiting the protease enzymes of the 
virus [15], [48]. Plasma therapy is another solution that 
the US Food and Drug Administration and WHO are 
looking for. It uses blood antibodies from the recovered 
patients, which is still in the experimental phase [49], [50].
Studies on children recommended the use 
of therapeutic drugs in reasonable and lowest doses 
at different ages, and like adults, antioxidants are the 
priority. In a study conducted in Wuhan, China, the use 
of antioxidants was recommended as adjunctive therapy 
for the entire high-sensitivity groups [45], [47], [47], [51].
Conclusion
Children are also diagnosed with COVID-19 
like adults. Despite the low prevalence of the disease in 
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children, the issue of prevention and immunosuppression 
in children is very important. The findings showed that 
children responded better to CoV than adults because 
of specific immune function in children.
Many studies have been published focusing 
on epidemiology, etiology, clinical manifestations, and 
diagnosis, prevention, and control. However, studies 
examining prevention and control measures have 
gradually increased. Government agencies have rapidly 
incorporated recent scientific findings into public policy 
at the community, regional, and national levels to slow or 
prevent further expansion of COVID-19. Our suggestion 
is to evaluate the difference in children’s immune system 
function in the face of CoV compared to the adults and 
to provide treatment options for children and those with 
weaker immune systems. It is also proposed that the 
scientific community conducts further studies to provide 
valid and effective ways to manage this type of public 
health hazard both short and long term.
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